<DOC>
	<DOCNO>NCT02174978</DOCNO>
	<brief_summary>The propose study Phase 1 study control human malaria infection ( CHMI ) design primarily evaluate safety FMP012 combine AS01B adjuvant system . AS01B proprietary current good manufacturing practice ( cGMP ) grade adjuvant manufacture GlaxoSmithKline ( GSK ) Biologicals . It formulation base liposome mixed immunostimulants monophosphoryl lipid ( MPL ) Quillaja saponaria ( QS ) -21 . The immunogenicity efficacy new candidate vaccine evaluate addition safety .</brief_summary>
	<brief_title>Phase 1 Clinical Trial With Controlled Human Malaria Infection ( CHMI ) Evaluate Safety Efficacy Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System Healthy Malaria-Naïve Adults</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult ( male nonpregnant , nonlactating female ) 18 50 year age ( inclusive ) time screen If subject female , Nonchildbearing potential ( ie , either surgically sterilize one year postmenopausal ) , abstinent use adequate contraceptive precaution ( eg , intrauterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive jelly , cream foam ; Norplant® DepoProvera® ) study must agree continue precaution three month challenge A negative pregnancy test time enrollment Free significant health problem establish medical history , laboratory , clinical examination enter study Subjects must low cardiac risk factor accord National Health Nutrition Examination Survey ( NHANES ) I criteria , medical history family history , blood pressure measurement , normal normal variant ECG Available participate reachable phone duration study ( approximately 814 month ) reachable phone 6 month post Controlled Human Malaria Infection ( CMHI ) followup No plan travel outside Washington DC area day challenge either completion treatment course ( postchallenge ) , subject remain uninfected , 28 day postchallenge No plan travel malaria endemic area course study Written inform consent must obtain subject screening procedure perform Subjects must score least 80 % correct multiplechoice quiz assess understand study If subject active duty military , must obtain approval supervisor per Walter Reed Army Institute Rese ( WRAIR ) Policy 1145 Any history malaria infection History travel P falciparum endemic area 3 month prior day first vaccination ( Vaccination Groups ) day challenge ( Infectivity Control Group ) Any history receive malaria vaccine Receipt license vaccine within 7 day prior first vaccination ( Note : subject encourage get recommend licensed preventive vaccination course study request schedule routine preventive vaccination least 7 day schedule FMP012/AS01B vaccination day ) History receipt malaria prophylaxis 2 month prior day first vaccination ( Vaccination Groups ) day challenge ( Infectivity Control Group ) History use antibiotic significant antimalarial activity ( example include tetracycline , doxycycline , clindamycin , azithromycin , sulfa drug ) course study period ( period start one month prior challenge , Infectivity Control Group ) Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine plan use study period . Any history allergic reaction anaphylaxis previous vaccination ( Vaccination Groups ) Allergy egg protein ( Vaccination Groups ) Pregnant ( positive βhuman chorionic gonadotropin test , βHCG ) lactate female screening plan become pregnant breastfeed time enrollment three month challenge Allergy antimalarial drug use medication know interact chloroquine ( CQ ) Significant ( eg , systemic ) hypersensitivity reaction mosquito bite ( local hypersensitivity reaction site mosquito bite exclusion criterion ) History sickle cell disease History psoriasis porphyria History splenectomy Any confirm suspected immunodeficiency , include HIV infection Administration chronic ( defined 14 day ) immunosuppressive drug immunemodifying drug within 6 month vaccination History autoimmune disease Family history congenital hereditary immunodeficiency Acute chronic , clinically significant , pulmonary , cardiovascular , endocrine , hepatic , renal functional abnormality , determine history , physical examination , laboratory evaluation Chronic active neurologic disease include seizure disorder chronic migraine headache Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period Any abnormal baseline laboratory screen test include : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) normal range , Creatinine normal range , Hemoglobin normal range , Platelet count normal range , Total white blood cell ( WBC ) count normal range Seropositive HIV Hepatitis C virus ( HCV ) hepatitis B surface antigen ( HBsAg ) positive Hepatomegaly , right upper quadrant abdominal pain tenderness An abnormal baseline screen ECG suggestive cardiac disease determine clinical investigator Suspected known current alcohol drug abuse determine medical history physical examination Any significant finding opinion PI would increase risk adverse outcome participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Malaria vaccine</keyword>
</DOC>